Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Cash from Discontinued Operations (2023 - 2024)

Mimedx recorded quarterly Cash from Discontinued Operations of 1000.0 in Q4 2024, up 200.0% quarter-over-quarter from 1000.0 in Q3 2024, and down 99.9% year-over-year from 987000.0 in Q1 2024.

Mimedx's Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 1000.0 for Q4 2024.

  • In Q4 2024, Cash from Discontinued Operations fell 99.9% year-over-year to 1000.0; the TTM figure through Sep 2025 stood at 1000.0 (down 98.21% YoY), while the FY2024 annual figure was 930000.0, up 88.61% from the prior year.
  • Cash from Discontinued Operations came in at 1000.0 for Q4 2024 at Mimedx, up from 1000.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 987000.0 in Q4 2023 to a low of 4648000.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Mimedx 530.69 Mn 370.92 Mn 41.62 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 1,000.00
Dec 31, 2024 1,000.00
Sep 30, 2024 -1,000.00
Sep 30, 2024 -1,000.00
Jun 30, 2024 -123,000.00
Jun 30, 2024 -123,000.00
Mar 31, 2024 -807,000.00
Mar 31, 2024 -807,000.00
Dec 31, 2023 987,000.00
Dec 31, 2023 987,000.00
Sep 30, 2023 -309,000.00
Sep 30, 2023 -309,000.00
Jun 30, 2023 -4.19 Mn
Jun 30, 2023 -4.19 Mn
Mar 31, 2023 -4.65 Mn
Mar 31, 2023 -4.65 Mn